Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT01197469
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT01197469
-
- Other papers using this trial's data
- Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01197469. Randomized; double masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?
- Condition
- Chronic Obstructive Pulmonary Disease
- Condition
- Pulmonary Hypertension
- Intervention (Drug)
- Tadalafil
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Dundee
- Collaborator
- Chief Scientist Office of the Scottish Government
- Collaborator
- NHS Tayside
- Collaborator
- NHS Fife
Record details
- Record id
cardio:ct-nct01197469- Content hash
31ec5930a01e6a0c8458641e7a24b650201845da59906892f7e254d54e93cab2